Drug Profile

Trastuzumab biosimilar - Nanogen Biopharmaceutical

Alternative Names: FACEPTOR; NNG-TMAB

Latest Information Update: 10 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Nanogen Biopharmaceutical Co
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action ERBB 2 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase III Breast cancer
Discontinued Gastric cancer

Most Recent Events

10 Jan 2025 Phase III development for breast cancer is ongoing in Vietnam
25 Mar 2021 Discontinued for Gastric cancer in Vietnam (IV) (Nanogen Biopharmaceutical pipeline, March 2021)
25 Mar 2021 Clinical development is ongoing in Breast cancer in Vietnam (IV) (Nanogen Biopharmaceutical pipeline, March 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com